Teva gets first approval for generic opioid reversal nasal spray

By Vassia Barba

- Last updated on GMT

(Image: Getty/BackyardProduction)
(Image: Getty/BackyardProduction)

Related tags: Teva, Naloxone, Opioid epidemic, Opioid

The US FDA approves the first generic naloxone nasal spray for opioid overdose, after prioritising the review of generic opioid reversal products.

Teva Pharmaceuticals received the final approval from the US Food and Drug Administration (FDA) for a generic naloxone nasal spray, developed to stop or reverse the effects of an opioid overdose.

The FDA tentatively approved​ Teva’s generic drug on June 8, 2018. Previously, a brand-name naloxone nasal spray was approved, as well as an auto-injector for use by those without medical training.

The FDA gave the green light for manufacturers to pursue approvals for over-the-counter naloxone products, as it aims to increase access to emergency treatment.

Deputy center director for regulatory programs in the FDA’s Center for Drug Evaluation and Research, Douglas Throckmorton stated that the FDA is also considering compulsory co-prescription of the spray “with all or some opioid prescriptions, to reduce the risk of overdose death​.”

The opioid crisis resulted in the death of almost 400,000 people in the US from 1999 to 2017, according to the Centers for Disease Control and Prevention​. On average, more than 130 Americans die every day from overdoses involving opioid prescription medications such as fentanyl, oxycodone, hydrocodone and morphine.

As part of its Five-Point Opioid Strategy​, in order to fight the opioid crisis, the US Department of Health and Human Services runs a State Opioid Response grant program, with a total amount of provided of $1.4bn (€1.25bn) for 2019.

Recently, the FDA issued two warning letters​ to operators of websites that market unapproved opioid medications, such as tramadol, increasing the number of warning letters issued regarding such behaviour to 25 since September 2017.

Related news

Show more

Related products

show more

From Candidate to Clinic- European Capabilities

From Candidate to Clinic- European Capabilities

Catalent Pharma Solutions | 22-Oct-2018 | Technical / White Paper

Catalent’s Nottingham, UK facility focuses on early stage development of small molecule drug candidates from the bench to clinic. This facility offers...

Strategies to Select and Deliver the Right Candidate

Strategies to Select and Deliver the Right Candidate

Catalent Pharma Solutions | 05-Mar-2018 | Technical / White Paper

Does your candidate have what it takes to succeed? Do you have the information needed to make the right decisions about your candidate’s path to the clinic?...


Optimizing vessel geometry for mag drive agitators

Steridose, Inc | 14-Sep-2017 | Technical / White Paper

The performance of a bottom mount magnetically driven agitator (mag drive mixer) is heavily dependent on its relationship with the vessel’s geometry, baffles,...

Related suppliers